BiotechTube

Hetrombopag

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioavailability Study

Conditions

Bioavailability Study

Trial Timeline

Sep 18, 2020 → Oct 30, 2020

NCT ID
NCT04688008

About Hetrombopag

Hetrombopag is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Bioavailability Study. The current trial status is completed. This product is registered under clinical trial identifier NCT04688008. Target conditions include Bioavailability Study.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT05394285Phase 2Recruiting
NCT04688008Phase 1Completed

Competing Products

20 competing products in Bioavailability Study

See all competitors
ProductCompanyStageHype Score
solifenacin succinate suspension + solifenacin succinate tabletAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
IpragliflozinAstellas PharmaPhase 1
33
ABT-450/r/ABT-267AbbViePhase 1
33
ABT-333AbbViePhase 1
33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2AstraZenecaPhase 1
33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orallyAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
selumetinib 75mg single doseAstraZenecaPhase 1
33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tubeAstraZenecaPhase 1
33
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423AstraZenecaPhase 1
33
Fostamatinib + Fostamatinib + Fostamatinib + FostamatinibAstraZenecaPhase 1
33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcgAstraZenecaPhase 1
33
D1400147 + D14000136 + D14000137 + Epanova®AstraZenecaPhase 1
33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of waterAstraZenecaPhase 1
33
NKTR-118 + KetoconazoleAstraZenecaPhase 1
33
TEPEZZA + EDPAmgenPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavirPfizerPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332PfizerPhase 1
32

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85